Sep 25, 2025

Sam Libby is President and Managing Director of TCB Capital Advisors, a healthcare-focused investment and advisory firm with a focus on improving patient outcomes in oncology, neurodegenerative diseases, and women's health. The firm evaluates early-stage companies based on the strength of clinical data, scientific and medical expertise, and technology, which may have been overlooked or struggled to raise funding. Trends TCB is keeping an eye on include diagnostics and preventive healthcare, as well as the growing interest in women's health, an underinvested sector that presents significant opportunities for innovation and investment.

Sam explains, "I think first and foremost, we look at the clinical data. So the way that we built TCD is that we have a team of experienced bankers and investors who work with early-stage companies. We also have on the other side of the house commercial experts and consultants who can do, I like to always say they can do all the things that bankers talk about. So, post-merger integration, building out the sales funnel, and applying for grants."

"The other side, which I believe is probably the most important, is the scientific, strategic, and clinical advisory boards. And so when you're looking at one of these early-stage companies, the first thing is, does the science work? Is the actual foundation for the company solid? And so having experts that can drill into that because it's very easy when you start talking about deals and an early-stage company, everyone gets excited by the vision of the CEO or founder." 

#TCBCapitalAdvisors #Healthcare #HeatlhcareInvestments #PatientOutcomes #Oncology #NeurodegenerativeDiseases #WomensHealth  

TCBcapitaladvisors.com

Listen to the podcast here